OncoMatch/Clinical Trials/NCT07033819
Neoadjuvant Treatment of Ovarian Cancer With Fuzuloparib in Combination With Apatinib
Is NCT07033819 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Neoadjuvant therapy with fuzuloparib in combination with apatinib and Chemotherapy for ovarian cancer.
Treatment: Neoadjuvant therapy with fuzuloparib in combination with apatinib · Chemotherapy · Maintenance treatment — In this study, investigators propose to use fuzuloparib and apatinib as neoadjuvant therapy for Homologous recombination deficiency （HRD）positive advanced ovarian cancer patients, aiming to explore the efficacy and safety of this 'de-chemotherapy' regimen as neoadjuvant therapy for advanced ovarian cancer, and to conduct genetically related subgroup analyses, to guide the precision therapy and provide a new therapeutic option for HRD-positive patients with advanced ovarian cancer. To provide a new treatment option In order to increase the R0 resection rate of surgery and reduce chemotherapy resistance, thus improving the prognosis and prolonging the survival of patients.
Check if I qualifyExtracted eligibility criteria
Cancer type
Ovarian Cancer
Disease stage
Required: Stage FIGO III, FIGO IV (FIGO)
with FIGO stage III-IV. Ineligibility for primary debulking surgery due to inability to achieve R0 resection or intolerance to surgery
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: anti-cancer treatment
Prior anti-cancer treatment for ovarian cancer.
Cannot have received: PARP inhibitor
Previous treatment with known or potential PARP inhibitors
Cannot have received: anti-angiogenic agent
Previous treatment with known or potential...anti-angiogenic agents
Cannot have received: molecularly targeted therapy
Receipt of other molecularly targeted therapies within 4 weeks prior to enrollment
Lab requirements
Blood counts
Hemoglobin (Hb) ≥90 g/L; ANC ≥1.5×10⁹/L; LC ≥0.5×10⁹/L; PLT ≥100×10⁹/L; WBC ≥3.0×10⁹/L and ≤15×10⁹/L
Kidney function
Serum creatinine ≤1.5×ULN, with creatinine clearance (CrCL) ≥60 mL/min (Cockcroft-Gault formula)
Liver function
ALT and AST ≤2.5×ULN; ALP ≤2.5×ULN; TBIL ≤1.5×ULN
Cardiac function
QTcF <470 ms for females
Adequate organ function, with laboratory results meeting the following criteria within 7 days prior to treatment initiation: Hemoglobin (Hb) ≥90 g/L. Absolute neutrophil count (ANC) ≥1.5×10⁹/L. Absolute lymphocyte count (LC) ≥0.5×10⁹/L. Platelet count (PLT) ≥100×10⁹/L. White blood cell count (WBC) ≥3.0×10⁹/L and ≤15×10⁹/L. ALT and AST ≤2.5×ULN. ALP ≤2.5×ULN. TBIL ≤1.5×ULN. Serum creatinine ≤1.5×ULN, with creatinine clearance (CrCL) ≥60 mL/min (Cockcroft-Gault formula). QTcF <470 ms for females.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify